ABG Sundal Collier acted as Sole Global Coordinator and Bookrunner in the rights issue of SEK 44 million in Neola Medical AB

Neola Medical AB (“Neola Medical”) has raised SEK 44 million in a rights issue. The funds will primarily be used to finance the development, validation and commercialisation of Neola®, a medical device that has the potential to revolutionise neonatal intensive care.
Neola Medical was founded in 2016 and develops Neola®, an innovative medical device that offer continuous lung monitoring and real-time alerts of life-threatening complications using a cutting-edge technology that measures lung volume changes and oxygen gas concentration. Every day, one in ten babies are born preterm, many of them with underdeveloped lungs that can advance to life-threatening conditions and disabilities later on in life. Neola® has the potential to provide better care, fewer days in intensive care and healthier lives for preterm born infants. The company’s shares are listed in Sweden on Nasdaq Firth North Growth Market.